Hanson Pharmaceuticals (03692): Amex® (ametinib mesylate tablets) was issued a drug registration certificate by the State Drug Administration for the fifth indication

Zhitong Finance App News, Hanson Pharmaceuticals (03692) announced that the Group's innovative drug, ametinib (ametinib mesylate tablets), obtained a drug registration certificate issued by the China National Drug Administration (“NMPA”), and approved the addition of “Amirol® combined with pimetrexate and platinum chemotherapy drugs for adults with epidermal growth factor receptor (“EGFR”) exon 19 deficiency or exon 21 (L858R) replacement mutations “First-line treatment for patients” indications. This is the fifth approved indication for Amelox®.